MedTrace Logo

The Effect of Colchicine on Food-related Effort-based Decision Making in Brain and Behaviour in Overweight and Obesity

NCT05785429 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2025-09-02

No results posted yet for this study

Summary

The main objective of the FLAIR-i study is to study the causal role of inflammation in affecting effort-based decision making in brain and behaviour in overweight and obesity, by comparing the effect of the anti-inflammatory agent colchicine vs. placebo.

Conditions

  • Overweight and Obesity

Interventions

DRUG

Colchicine 0.5 MG

Participant in the intervention group receive one tablet of 0.5mg colchicine per day for 12 weeks.

DRUG

Placebo

Participants in the intervention group receive one tablet of placebo per day for 12 weeks.

Sponsors & Collaborators

  • Radboud University Medical Center

    collaborator OTHER

  • HAN University of Applied Sciences

    collaborator OTHER

  • Donders Centre for Cognitive Neuroimaging

    lead OTHER

Principal Investigators

  • Esther Aarts, Prof.dr. · Donders Centre for Cognitive Neuroimaging

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-02
Primary Completion
2025-01-20
Completion
2025-01-20

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05785429 on ClinicalTrials.gov